Hints and tips:
Related Special Reports
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...Money gleaned from the deal will help fund its dealmaking strategy, which includes rebuilding its oncology business after former chief executive Sir Andrew Witty sold its products in the area to Novartis...
...And Microsoft, through its cloud computing platform Azure, has taken on expansive projects including one with pharmaceutical group Novartis that covers everything from manufacturing and finance operations...
...In the field of cardiovascular medicine, for instance, Novartis has a mass of data drawn, over the past decade, from trials involving 100,000 patients....
...Sanofi, which wants incoming boss — ex-Novartis executive Paul Hudson — to improve its digital capabilities, is in line with its competition....
Sales growth and drug approvals accelerate in world’s second-largest market
...Novartis, for example, was fined by South Korean authorities last year and had products suspended for three months on allegations of offering payments to doctors to recommend its drugs....
...The pan-European FTSE Eurofirst 300 index fell 1 per cent as poorly received results and guidance from BASF and Novartis undermined both companies’ shares....
...Intellia Therapeutics raised $15m last year before signing a collaboration with Novartis in January....
...Examples include France’s Schneider Electric, which has invested in an emerging market solar finance company; Nestlé, Novartis and Vodafone, which are collaborating to improve the business ecosystem in Kenya...
...Joe Jimenez, chief executive of Novartis, the Swiss drugs group, says the health and technology industries must share expertise....
...(Financial Times) Deals fever grips pharmaceuticals industry: A near $50bn takeover battle for the maker of Botox and a multibillion-dollar asset swap between Novartis and GlaxoSmithKline have intensified...
...J&J and Novartis are the largest and second largest players in the contact lens market; Bausch is fourth....
...Of the big 11 drugmakers, only Novartis delivered a worse return to shareholders last year....
...The drug was being developed and planned to be brought to market by Novartis, the Swiss pharmaceuticals company....
...Novartis declined to comment. Genentech, now controlled by Roche, has been marketing Lucentis, while licensing the rights to the drug in Europe to Novartis....
...According to a presentation given to prospective investors, Sir Christopher has already struck a deal with Merck and is in discussions with companies including AstraZeneca, Novartis and Pfizer....
...It also benefited from a strategic shake-up after the appointment of Mr Ebeling from Novartis as its new chief executive in 2009....
...In pharmaceuticals, the government engineered the merger between Sanofi and Aventis to create a new champion rather than allow the Swiss Novartis to swallow it up....
...Companies which he believed were better prepared to weather patent expiries included Novartis and Roche of Switzerland, which have diversified away from chemical-based patented drugs even when some of their...
...Diversity is no cure-all: both Novartis and GSK reported lower profits this week....
...Novartis produces one authorised vaccine with a patented chemical adjuvant that enhances the body’s immune response. Other companies are working on rival adjuvants....
...After all, it sold an initial 25 per cent stake in its US eye care company Alcon to Novartis for about $11bn last year with the option to sell its remaining 52 per cent stake to the Swiss pharmaceutical...
...Monday’s deal comes less than a year after the Swiss drugmaker Novartis said it would buy up to a 77 per cent stake in Alcon, the eye care market leader, from Nestlé in a two-step transaction worth as much...
...Roche of Switzerland, best known for its valium sedative and locked in a battle for drug company supremacy with its Swiss rival Novartis, is preparing a fresh offer for Genentech, the US biotechnology company...
International Edition